Cronin, Ryan and Brooke, Greg N and Prischi, Filippo (2021) The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance. Oncogene, 40 (22). pp. 3775-3785. DOI https://doi.org/10.1038/s41388-021-01810-9
Cronin, Ryan and Brooke, Greg N and Prischi, Filippo (2021) The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance. Oncogene, 40 (22). pp. 3775-3785. DOI https://doi.org/10.1038/s41388-021-01810-9
Cronin, Ryan and Brooke, Greg N and Prischi, Filippo (2021) The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance. Oncogene, 40 (22). pp. 3775-3785. DOI https://doi.org/10.1038/s41388-021-01810-9
Abstract
Prostate cancer (PCa) is the second most commonly occurring cancer in men, with over a million new cases every year worldwide. Tumor growth and disease progression is mainly dependent on the Androgen Receptor (AR), a ligand dependent transcription factor. Standard PCa therapeutic treatments include androgen-deprivation therapy and AR signaling inhibitors. Despite being successful in controlling the disease in the majority of men, the high frequency of disease progression to aggressive and therapy resistant stages (termed castrate resistant prostate cancer) has led to the search for new therapeutic targets. The p90 ribosomal S6 kinase (RSK1-4) family is a group of highly conserved Ser/Thr kinases that holds promise as a novel target. RSKs are effector kinases that lay downstream of the Ras/Raf/MEK/ERK signaling pathway, and aberrant activation or expression of RSKs has been reported in several malignancies, including PCa. Despite their structural similarities, RSK isoforms have been shown to perform nonredundant functions and target a wide range of substrates involved in regulation of transcription and translation. In this article we review the roles of the RSKs in proliferation and motility, cell cycle control and therapy resistance in PCa, highlighting the possible interplay between RSKs and AR in mediating disease progression. In addition, we summarize the current advances in RSK inhibitor development and discuss their potential clinical benefits.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Nuclear receptors; Phosphorylation; Prostate cancer |
Divisions: | Faculty of Science and Health Faculty of Science and Health > Life Sciences, School of |
SWORD Depositor: | Unnamed user with email elements@essex.ac.uk |
Depositing User: | Unnamed user with email elements@essex.ac.uk |
Date Deposited: | 19 May 2021 09:15 |
Last Modified: | 07 Aug 2024 20:43 |
URI: | http://repository.essex.ac.uk/id/eprint/30371 |
Available files
Filename: s41388-021-01810-9.pdf
Licence: Creative Commons: Attribution 3.0